GT200900004A - Inhibidores de tirosina quinasa - Google Patents

Inhibidores de tirosina quinasa

Info

Publication number
GT200900004A
GT200900004A GT200900004A GT200900004A GT200900004A GT 200900004 A GT200900004 A GT 200900004A GT 200900004 A GT200900004 A GT 200900004A GT 200900004 A GT200900004 A GT 200900004A GT 200900004 A GT200900004 A GT 200900004A
Authority
GT
Guatemala
Prior art keywords
thyrosine
kinase inhibitors
kinase
thyrosine kinase
useful
Prior art date
Application number
GT200900004A
Other languages
English (en)
Inventor
Christopher J Dinsmore
Matthew H Katcher
Alan B Northrup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900004A publication Critical patent/GT200900004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS UTILES PARA UNIR A Y/O MODULAR LA ACTIVIDAD DE UNA TIROSINA QUINASA Y EN PARTICULAR A UNA TIROSINA QUINASA DE RECEPTOR EN LA QUE DICHA QUINASA RECEPTORA ES UN MIEMBRO DE LA SUBFAMILIA MET POR LO QUE SON DE UTILIDAD EN CUADROS DE HIPERPROLIFERACION CELULAR TALES COMO EL CANCER.
GT200900004A 2006-07-10 2009-01-09 Inhibidores de tirosina quinasa GT200900004A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81976406P 2006-07-10 2006-07-10

Publications (1)

Publication Number Publication Date
GT200900004A true GT200900004A (es) 2010-04-13

Family

ID=38923821

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900004A GT200900004A (es) 2006-07-10 2009-01-09 Inhibidores de tirosina quinasa

Country Status (24)

Country Link
US (2) US8222269B2 (es)
EP (1) EP2049494B1 (es)
JP (2) JP4203121B1 (es)
KR (1) KR20090026187A (es)
CN (1) CN101535268B (es)
AR (1) AR061804A1 (es)
AU (1) AU2007273081B2 (es)
BR (1) BRPI0713941A2 (es)
CA (1) CA2656578C (es)
CO (1) CO6190518A2 (es)
CR (1) CR10560A (es)
EC (1) ECSP099051A (es)
ES (1) ES2497493T3 (es)
GT (1) GT200900004A (es)
HN (1) HN2009000018A (es)
IL (1) IL196337A0 (es)
MA (1) MA30631B1 (es)
MX (1) MX2009000410A (es)
NO (1) NO20090608L (es)
PE (1) PE20080275A1 (es)
RU (1) RU2009104303A (es)
TW (1) TW200813021A (es)
WO (1) WO2008008310A2 (es)
ZA (1) ZA200900019B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550478B2 (en) 2005-06-23 2009-06-23 Merck & Co. Inc. Tyrosine kinase inhibitors
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2009141290A2 (en) * 2008-05-21 2009-11-26 Basf Se Substituted pyridin-4-ylmethyl sulfonamides
EP2482821A4 (en) * 2009-09-30 2013-03-06 Merck Sharp & Dohme CRYSTALLINE HYDROCHLORIDE SALTS FROM C-MET KINASE INHIBITORS
WO2011039527A1 (en) 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
BR112014024251A8 (pt) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
EP3027655B1 (en) * 2013-07-30 2019-08-21 Blueprint Medicines Corporation Ntrk2 fusions
EP3027654B1 (en) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
DK3471722T3 (da) * 2016-06-17 2023-12-04 Univ Pennsylvania Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (es) * 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
US6365588B1 (en) * 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ATE201195T1 (de) * 1995-10-16 2001-06-15 Kyowa Hakko Kogyo Kk Tricyclische verbindungen
HUP9904067A2 (hu) 1996-09-13 2000-05-28 Schering Corporation A G-protein-funkció gátlására és daganatos betegségek kezelésére alkalmazható triciklusos vegyületek
IL128926A0 (en) 1996-09-13 2000-02-17 Schering Corp Substituted benzocycloheptapyridines useful as inhibitors of farnesyl-protein transferase
MXPA04002682A (es) * 2001-09-19 2004-06-18 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
WO2003084931A1 (en) 2002-04-02 2003-10-16 Merck & Co., Inc. 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
CA2573103A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
TW200738638A (en) * 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
US7550478B2 (en) * 2005-06-23 2009-06-23 Merck & Co. Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
ECSP099051A (es) 2009-02-27
NO20090608L (no) 2009-04-14
TW200813021A (en) 2008-03-16
MX2009000410A (es) 2009-01-27
CN101535268A (zh) 2009-09-16
CA2656578A1 (en) 2008-01-17
RU2009104303A (ru) 2010-08-20
ES2497493T3 (es) 2014-09-23
JP5245045B2 (ja) 2013-07-24
US20090203684A1 (en) 2009-08-13
AR061804A1 (es) 2008-09-24
EP2049494A2 (en) 2009-04-22
AU2007273081B2 (en) 2011-04-07
IL196337A0 (en) 2009-09-22
JP2009512698A (ja) 2009-03-26
WO2008008310A3 (en) 2008-05-15
CO6190518A2 (es) 2010-08-19
HN2009000018A (es) 2011-01-24
AU2007273081A1 (en) 2008-01-17
EP2049494B1 (en) 2014-06-25
CN101535268B (zh) 2012-11-14
JP4203121B1 (ja) 2008-12-24
KR20090026187A (ko) 2009-03-11
WO2008008310A2 (en) 2008-01-17
US8222269B2 (en) 2012-07-17
CR10560A (es) 2009-02-26
MA30631B1 (fr) 2009-08-03
US8101603B2 (en) 2012-01-24
BRPI0713941A2 (pt) 2012-12-04
US20090012076A1 (en) 2009-01-08
ZA200900019B (en) 2009-11-25
PE20080275A1 (es) 2008-04-03
JP2009173622A (ja) 2009-08-06
CA2656578C (en) 2012-09-04

Similar Documents

Publication Publication Date Title
GT200900004A (es) Inhibidores de tirosina quinasa
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
GT200800209A (es) Compuestos organicos
CL2007001995A1 (es) Compuestos derivados de pirrolotriazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el cancer.
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
EA200970140A1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
BRPI0813831A2 (pt) Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
DE602007012072D1 (de) Orantagonisten
MX370429B (es) Composiciones farmacéuticas que comprenden bi-1356 y metformina.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
BRPI0912356A2 (pt) compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
CL2012000887A1 (es) Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
PA8667201A1 (es) Nuevos compuestos farmaceuticos
HN2005000477A (es) Compuestos de aminoheteroarilo sustituidos con piraol como inhibidores de proteina quinasa
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2007002107A1 (es) Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
GT200900027A (es) Compuestos organicos
SV2010003648A (es) Inhibidores del receptor de quimioquinas cxcr3